Form 4: Fortress Biotech Director Receives Restricted Stock Grant

Fortress Biotech Director Dov Klein was granted 27,322 restricted shares, which were deferred into share units with a vesting schedule through 2029.

Summary

• Dov Klein, a Director of Fortress Biotech, Inc. (FBIO), was granted 27,322 shares of restricted common stock.
• The grant was made pursuant to the Issuer's 2013 Stock Incentive Plan, as amended.
• The restricted shares have a vesting schedule: one-third will vest on January 1, 2027, 2028, and 2029, contingent on continued service.
• Mr. Klein elected to defer 100% of these restricted shares into deferred share units under the Issuer's Deferred Compensation Plan for Directors.
• Vested deferred shares will be delivered in January of the year following termination of service, or earlier upon death or a change in control of the Issuer.
• Following this transaction, Mr. Klein beneficially owns 130,105 shares, which includes 102,668 shares underlying deferred restricted stock units.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally a neutral to slightly positive signal as it aligns management interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of restricted stock aligns the director's long-term interests with those of the shareholders.
• The deferred compensation plan provides a structured approach to executive compensation and retention.

Negatives

• The shares are restricted and subject to a multi-year vesting schedule, meaning no immediate liquidity for the director.
• The grant price was $0, indicating it is compensation rather than a direct purchase at market value.

Risks

• The restricted shares are subject to forfeiture if the director's service terminates before the vesting dates.
• The value of the deferred share units is tied to the future stock price of Fortress Biotech, Inc., exposing the director to market risk.

Future Outlook

The vesting schedule for the granted shares extends through January 2029, indicating an expectation of continued service from the director. The deferral into share units means the actual delivery of shares will occur after the director's termination of service, or earlier under specific conditions.

Industry Context

Equity grants, particularly restricted stock and deferred share units, are a common form of compensation for directors in publicly traded companies, especially in the biotech sector. This practice aims to align the interests of directors with long-term shareholder value creation and to retain key talent.

Comparison to Industry Standards

• The use of restricted stock and deferred compensation plans for director remuneration is a standard practice across various industries, including biotechnology.
• The multi-year vesting schedule is typical for equity grants designed for long-term retention and performance alignment, comparable to practices at companies like Amgen or Gilead Sciences, which also utilize similar equity-based compensation structures for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of restricted stock to Dov Klein, a Director of Fortress Biotech, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of restricted stock aligns the director's financial interests with long-term shareholder value, potentially encouraging decisions that benefit the company's stock performance.
• Employees: While not directly impacting general employees, such compensation structures for directors can set a precedent for equity-based incentives within the company.

Next Steps

• One-third of the deferred share units are scheduled to vest on January 1, 2027, 2028, and 2029, subject to continued service.
• Vested deferred shares will be delivered to the reporting person in January of the year following their termination of service, or earlier upon death or a change in control of the Issuer.

Key Dates

Keywords

Fortress Biotech, FBIO, Dov Klein, restricted stock, stock grant, director compensation, deferred compensation, SEC Form 4, insider transaction